source
- Novartis says it will keep seeking sub-$2 billion bolt-on deals worldwide, staying geography-agnosticNovartis CEO Vas Narasimhan told investors on the second‑quarter earnings call that the company will continue to pursue bolt‑on acquisitions below $2 billion and has no plans to overhaul its busine…
- FDA issues warning letter to Alembic Pharmaceuticals over missing patient consent in clinical studyThe U.S. Food and Drug Administration sent a warning letter to Indian generic manufacturer Alembic Pharmaceuticals after it was found to have failed to obtain informed consent from participants in…